Study S000751

A Randomized, Double-blind, Placebo-controlled Phase III Study Evaluating the Efficacy and Safety of IBI362 in Chinese Participants With Obesity or Overweight (GLORY-1)

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT05607680
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: TRIPLE
Status: COMPLETED
Enrollment: 610
Start: 2022-11-14
Primary completion: 2023-08-21
Lead sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Conditions: Obesity Or Overweight
Interventions: DRUG:Placebo; DRUG:IBI362
Results posted: FALSE

Registered primary outcomes

Percent Change from Baseline in Body Weight [Baseline, Week 32]
Percentage of Participants who Achieve ≥5% Body Weight Reduction [Week 32]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0013080	Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. Ji L, The New England journal of medicine	2025	Randomized trial	PMID 40421736 DOI	cites ClinicalTrials.gov:NCT05607680; registry reference DERIVED:40421736
R0037038	1857-LB: Improvement of Liver Steatosis by Mazdutide in Chinese Participants with Overweight or Obesity—An Exploratory Analysis of GLORY-1 Linong Ji, Diabetes	2024	Randomized trial	DOI	cites ClinicalTrials.gov:NCT05607680
R0039045	1856-LB: Efficacy and Safety of Mazdutide in Chinese Participants with Overweight or Obesity (GLORY-1) Linong Ji, Diabetes	2024	Randomized trial	DOI	cites ClinicalTrials.gov:NCT05607680